BACKGROUND: Chromatin is an extraordinarily complex structure. Much of this complexity results from the presence of numerous histone post-translational modifications and histone variants. Alterations in the patterns of histone post-translational modifications are emerging as a feature of many types of @entity5 and have been shown to have prognostic value. RESULTS: We have applied a liquid chromatography/mass spectrometry-based approach to comprehensively characterize the histone proteome in primary samples from @entity1072 ( @entity1072 ) @entity1 , as well as bladder and @entity0 cell culture models. When compared to non-malignant @entity1075 +  B cells from healthy donors, the @entity1072 histone proteome showed a distinct signature of differentially expressed species, spanning all the histones studied and including both post-translationally modified species and unmodified, non-allelic replication-dependent histone isoforms. However, the large changes in histone H3 and H4 that are characteristic of many @entity5 types were not observed. One of species of H2A (mass  =  14,063  Da) was the most strongly associated with time to treatment in @entity1072 @entity1 . @entity1072 @entity1 samples also demonstrated histone profiles that were distinct from those of the bladder and @entity0 cells. CONCLUSIONS: Signatures of histone profiles are complex and can distinguish between healthy individuals and @entity1072 @entity1 and may provide prognostic markers. In addition, histone profiles may define tissue specific @entity5 .

Proteomic profiling identifies specific histone species associated with leukemic and XXXX cells.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1075 :: ('930', 'Gene') :: ['CD19'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancies'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
